Bait protein expressed as a DNA binding domain (DBD) fusion and prey expressed as a transcriptional activation domain (TAD) fusion and interaction measured by reporter gene activation.

Publication

Bcl2L13 is a ceramide synthase inhibitor in glioblastoma.

Jensen SA, Calvert AE, Volpert G, Kouri FM, Hurley LA, Luciano JP, Wu Y, Chalastanis A, Futerman AH, Stegh AH

Therapy resistance is a major limitation to the successful treatment of cancer. Here, we identify Bcl2-like 13 (Bcl2L13), an atypical member of the Bcl-2 family, as a therapy susceptibility gene with elevated expression in solid and blood cancers, including glioblastoma (GBM). We demonstrate that mitochondria-associated Bcl2L13 inhibits apoptosis induced by a wide spectrum of chemo- and targeted therapies upstream of ... [more]

Proc Natl Acad Sci U S A Apr. 15, 2014; 111(15);5682-7 [Pubmed: 24706805]

Throughput

Low Throughput

Curated By

BioGRID

Interaction Summary

BCL2L13

Gene Ontology Biological Process

Gene Ontology Molecular Function

cysteine-type endopeptidase activator activity involved in apoptotic process [NAS]

Gene Ontology Cellular Component

PCBP1